Pharma 202

www.pwc.com/pharma2020

Pharma 2020:
Supplying the future
Which path will you take?
Pharmaceuticals and
Life Sciences

Previous publications in this series include:

Published in June 2007, this paper highlights a number of issues that will have a major bearing on the industry by
2020. The publication outlines the changes we believe will best help pharmaceutical companies realise the potential the future holds to enhance the value they provide to shareholders and society alike.

Pharmaceuticals

Pharma 2020: The vision
Which path will you take?*

*connectedthinking

Pharmaceuticals and Life Sciences

Pharma 2020: Challenging business models
Which path will you take?

Fourth in the Pharma 2020 series and published in April
2009, this report highlights how Pharma’s fully integrated business models may not be the best option for the pharma industry in 2020; more creative collaboration models may be more attractive. This paper also evaluates the advantages and disadvantages of the alternative business models and how each stands up against the challenges facing the industry.



Pharma 2020: The vision

#

This report, published in June
2008, explores opportunities to improve the R&D process. It proposes that new technologies will enable the adoption of virtual R&D; and by operating in a more connected world the industry, in collaboration with researchers, governments, healthcare payers and providers, can address the changing needs of society more effectively. Pharmaceuticals and Life Sciences

Pharma 2020: Virtual R&D
Which path will you take?

Pharma 2020: Virtual R&D

Pharmaceuticals and Life Sciences

Pharma 2020: Marketing the future
Which path will you take?

1

Published in February 2009, this paper discusses the key forces reshaping the pharmaceutical marketplace, including the growing power of healthcare payers, providers and patients, and the changes required to

References: EvaluatePharma, “World Preview 2016” (May 2010). 4. Agnes Shanley, “Toyota’s Meltdown: Lessons for Pharma on its Lean Journey”, PharmaManufacturing.com (2010), http://www. 8. World Health Organisation, “Primary healthcare now more than ever” (2008). com/2010/09/special-report-global-water-shortages-will-pose-major-challenges.html; and “Climate Change, Water, and Risk”, Natural Resources Defense Council (July 16, 2010), http://www.nrdc.org/globalwarming/watersustainability/ 16. “Lift-off”, The Economist (November 4, 2010), http://www.economist.com/node/17414216 17. PricewaterhouseCoopers, “Pharma 2020: Taxing times ahead” (2009). EmaxHealth (November 9, 2010), http://www.emaxhealth.com/1506/successful-clinical-trial-pfizer-rheumatoid-arthritis-drug-tasocitinib 19. FDA, “Guidance for Industry Process Validation: General Principles and Practices” (November 2008). 21. Arseus website, http://www.arseus.com/en/17 22. GTC Biotherapeutics, “Form 10-K” (March 12, 2010), http://www.faqs.org/sec-filings/100312/GTC-BIOTHERAPEUTICS-INC_10K/#ixzz18m99ATaB 23. Lois Rogers, “Hop over here, Flopsy Bunny, stroke victims need your milk”, The Sunday Times (January 17, 2010), http://www.timesonline.co.uk/ tol/news/science/medicine/article6991031.ece org/articles/dna-fingerprinting-method-may-thwart.html 25. Brian Dolan, “Novartis, Proteus pilot to lead to exclusive deal?” mobihealthnews (September 22, 2009), http://mobihealthnews.com/4513/ abbottlaboratories/; and Boehringer-Ingelheim, http://www.boehringer-ingelheim.com/contract_manufacturing.html 27. BCC Research, “Contract Pharmaceutical Manufacturing, Research and Packaging” (October 2009). 28. Nestlé press release, “Nestlé and Mars Join Forces for Christmas Confectionery Deliveries” (December 14, 2009), http://www.nestle.co.uk/ PressOffice/PressReleases/December/NestleAndMarsJoinForcesForChristmasConfectioneryDeliveries.htm. 29. John Conroy, “Cold-Chain Challenges Heat Up”, Pharmaceutical & Medical Packaging News (July 13, 2009), http://www.pmpnews.com/article/ cold-chain-challenges-heat; and UPS, “Temperature True”, http://healthcare.ups.com/resources/temperaturetrue.pdf 30. UPS, “UPS Supply Chain Solutions Group Provides Fourth-Party Logistics Support for Alcatel eND’s Supply Chain” (2004), https://www.ups-scs. coverstory/88/8806cover2.html 32. Marsh, “Building a Safe and Secure Pharmaceutical Supply Chain” (October 2008), http://global.marsh.com/risk/supply_chain/ BuildingSafePharmaSupplyChainsOct2008-2.pdf 33. Catharine Paddock, “FDA Says Heparin Contamination Is A Worldwide Problem”, Medical News Today (April 22, 2008), http://www. medicalnewstoday.com/articles/104874.php; and Charlie Mead, “Baxter lawsuits spike two years after heparin recall”, Medill Reports (January 13, 2010), http://news.medill.northwestern.edu/chicago/news.aspx?id=153503 34. Axendia, “Achieving Global Supply Chain Visibility, Control and Collaboration in Life Sciences: Regulatory Necessity, Business Imperative” (2010).